ReviewDrug design, development and therapy2026
Pharmacological Interventions in the Management of Sports Injuries: A Review of Clinical Use, Dosage Forms, and Anti-Doping Considerations.
Review in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Role of Athlete Support Personnel in Anti-Doping: A Narrative Review of Contemporary Evidence.Healthcare (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sports injuries are common among active adults and frequently require pharmacological interventions to control pain, reduce inflammation, and support functional recovery. Clear understanding of drug use patterns in clinical trials and their alignment with anti-doping regulations is essential for safe and ethical sports medicine practice. Objective: To identify and characterize pharmacological interventions investigated in clinical trials for sports injuries in adults, focusing on drug class, dosage form, route of administration, and World Anti-Doping Agency classification. Methods: A retrospective registry-based analysis was conducted using ClinicalTrials.gov on 13 March 2025. Trials registered under the condition Sport Injury and involving adults aged 18 to 64 years were included, obtaining 426 studies. Pharmacological agents explicitly listed in the Interventions field were extracted and classified by therapeutic category, dosage form, route of administration, and World Anti-Doping Agency status according to the 2024 Prohibited List. Results: Twenty pharmacological agents were identified across multiple therapeutic classes, including non-steroidal anti-inflammatory drugs, corticosteroids, local anesthetics, biological therapies, and nutritional supplements. Oral, injectable, and topical formulations were most commonly reported. Non-steroidal anti-inflammatory drugs and local anesthetics represented the predominant drug classes. Most identified agents were permitted under World Anti-Doping Agency regulations when used via appropriate routes, whereas systemic corticosteroids were restricted during competition. Conclusion: Clinical trials evaluating pharmacological management of sports injuries predominantly focus on non-steroidal anti-inflammatory drugs and local anesthetics, reflecting current clinical practice. The findings highlight the importance of route-specific prescribing and regulatory awareness to ensure anti-doping-compliant pharmacotherapy in athletic populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.